In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $140.00. The company’s shares closed yesterday at $112.77.
Brennan covers the Healthcare sector, focusing on stocks such as Illumina, Pacific Biosciences, and NeoGenomics. According to TipRanks, Brennan has an average return of 6.9% and a 51.69% success rate on recommended stocks.
In addition to TD Cowen, Illumina also received a Hold from Canaccord Genuity’s Kyle Mikson CFA in a report issued on May 7. However, today, Stifel Nicolaus maintained a Buy rating on Illumina (NASDAQ: ILMN).
The company has a one-year high of $213.91 and a one-year low of $89.00. Currently, Illumina has an average volume of 1.61M.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ILMN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Illumina (ILMN) Company Description:
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
